학술논문
First-in-human dose-escalation trial of BI 764532, a delta-like ligand 3 (DLL3)/CD3 IgG-like T-cell engager in patients (pts) with DLL3-positive (DLL3+) small-cell lung cancer (SCLC) and neuroendocrine carcinoma (NEC).
Document Type
Article
Author
Source
Journal of Clinical Oncology; 2023 Supplement 16, Vol. 41, p8502-8502, 1p
Subject
Language
ISSN
0732183X